For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
Preclinical and Clinical Evidence for Optimal Healing and Safety with SYNERGY
SYNERGY™ is the only FDA-approved, everolimus-eluting platinum chromium stent with an abluminal bioabsorbable PLGA polymer coating designed to optimize healing.
SYNERGY demonstrates superior healing responses compared to DES in atherosclerotic rabbit iliac artery model
In an atherosclerotic rabbit iliac artery model, 24 rabbits were fed an atherogenic diet and their iliac arteries underwent endothelial denudation using a balloon catheter. Bioabsorbable-polymer coated DES (BP-DES) SYNERGY (S, n=8), permanent polymer-DES Resolute Integrity (R, n=8), or BP-DES Nobori (N, n=8) stents were then implanted in each iliac artery. Scanning Electron Microscopy results at 28 days demonstrate that the percentage of uncovered strut area was lowest for SYNERGY (S, n=8) followed by Resolute Integrity (R, n=8), and highest for Nobori (N, n=8) (overall P<0.001). The difference between SYNERGY and Nobori was statistically significant.1Neoatherosclerosis and inflammation were compared in SYNERGY (S, n=7), Resolute Integrity (R, n=6), and Nobori (N, n=7) through histological assessment at 90 days. The ‘Neoatherosclerosis Score’ for SYNERGY was lowest across all stents and was statistically lower than Resolute Integrity (overall P=0.034). The histological analysis also demonstrated that the ‘Inflammation Score’ was significantly lower in SYNERGY-treated arteries than in those treated with either Resolute Integrity or Nobori (overall P<0.001). Together, these data support superior vessel healing with the SYNERGY stent compared to other BP-DES or permanent polymer-DES.1 Nakazawa G, Torii S, Ijichi T, Nagamatsu H, Ohno Y, Kurata F, Yoshikawa A, Nakano M, Shinozaki N, Yoshimachi F, Ikari Y. Comparison of Vascular Responses Following New-Generation Biodegradable and Durable Polymer-Based Drug-Eluting Stent Implantation in an Atherosclerotic Rabbit Iliac Artery Model. J Am Heart Assoc. 2016; 5:e003803doi:10.1161/JAHA.116.003803.
Angioscopic Evidence of Healing with SYNERGY at 1 to 3 Years
Two SYNERGY stents were implanted in a diffusely diseased left anterior descending artery in a 58 year-old male with angina at rest. Thirteen months following stent implantation, angioscopic images demonstrated covered struts with a thicker neointima (compared to second generation DES), similar to bare metal stents. Thirty-four months following implantation, angioscopic images demonstrated continued complete strut coverage with neither red thrombus nor neoatherosclerosis visible. These angioscopic images provide evidence of continued healing out to three years with the SYNERGY stent.2
SYNERGY - 13mo
SYNERGY - 34mo
2 Ueno, T. Presented at TCT 2016.Case study not necessarily representative of all cases. Results in other cases may vary.
The SYNERGY Stent Receives FDA Approval for Use in Diabetic Patients
SYNERGY received FDA approval for use in patients with Diabetes Mellitus. The EVOLVE II Diabetes Substudy was a prospective, single-arm, multi-center, non-randomized study that included 466 diabetic patients treated with the SYNERGY Stent (263 patients from the SYNERGY Cohort of the EVOLVE II RCT and 203 patients from the single-arm Diabetes Study). The primary endpoint was Target Lesion Failure (TLF) at 12 months compared to a performance goal based on historical results in diabetic patients. The 12-month TLF rate of 7.5% was well within the performance goal of 14.5% (P<0.0001).3
3 Kereiakes DJ, Meredith IT, Masotti M, Carrié D, Moreno R, Erglis A, Mehta SR, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe RL, Reitman A, Janssens L, Christen T, Dawkins KD, Windecker S. Safety and Efficacy of a Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent in Patients with Diabetes: the EVOLVE II Diabetes Substudy. EuroIntervention 2016; doi: 10.4244/EIJ-D-16-00643.